Arcus Biosciences
RCUS
RCUS
173 hedge funds and large institutions have $1.33B invested in Arcus Biosciences in 2022 Q2 according to their latest regulatory filings, with 53 funds opening new positions, 64 increasing their positions, 32 reducing their positions, and 35 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
16% less capital invested
Capital invested by funds: $1.59B → $1.33B (-$259M)
38% less funds holding in top 10
Funds holding in top 10: 8 → 5 (-3)
39% less call options, than puts
Call options by funds: $17.6M | Put options by funds: $28.9M
Holders
173
Holding in Top 10
5
Calls
$17.6M
Puts
$28.9M
Top Buyers
| 1 | +$101M | |
| 2 | +$42.7M | |
| 3 | +$19.5M | |
| 4 |
Goldman Sachs
New York
|
+$18.4M |
| 5 |
FC
Finepoint Capital
Boston,
Massachusetts
|
+$13.6M |
Top Sellers
| 1 | -$103M | |
| 2 | -$80.9M | |
| 3 | -$28.8M | |
| 4 |
TCM
TimesSquare Capital Management
New York
|
-$25.9M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$23.9M |